Bio-Rad Laboratories (BIO) — insider trading
Health Care
Bio-Rad Laboratories (BIO) has 34 reported SEC Form 4 insider transactions in our data, including 2 open-market sales among the most recent 34 (latest 2026-05-11).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-05-11 | ENGELHARDT EVA ANETTE | Officer (EVP, President, CDG) | Open-market sale | 550 | $246.54 | $135.6K | Form 4 |
| 2026-04-24 | ENLOE COURTNEY C | Officer (EVP, General Counsel & Sec) | Option exercise / conversion (derivative) | 186 | $0.00 | $0 | Form 4 |
| 2026-04-24 | ENLOE COURTNEY C | Officer (EVP, General Counsel & Sec) | Shares withheld for taxes / exercise cost | 77 | $287.84 | $22.2K | Form 4 |
| 2026-04-24 | ENLOE COURTNEY C | Officer (EVP, General Counsel & Sec) | Option exercise / conversion | 186 | $0.00 | $0 | Form 4 |
| 2026-04-24 | Lakkaraju Roop Kalyan | Officer (EVP, Chief Financial Officer) | Option exercise / conversion (derivative) | 1,078 | $0.00 | $0 | Form 4 |
| 2026-04-24 | Lakkaraju Roop Kalyan | Officer (EVP, Chief Financial Officer) | Shares withheld for taxes / exercise cost | 420 | $287.84 | $120.9K | Form 4 |
| 2026-04-24 | Lakkaraju Roop Kalyan | Officer (EVP, Chief Financial Officer) | Option exercise / conversion | 1,078 | $0.00 | $0 | Form 4 |
| 2026-04-21 | PINKSTON ARNOLD A | Director | Option exercise / conversion (derivative) | 407 | $0.00 | $0 | Form 4 |
| 2026-04-21 | PINKSTON ARNOLD A | Director | Grant / award / vesting (derivative) | 369 | $0.00 | $0 | Form 4 |
| 2026-04-21 | PINKSTON ARNOLD A | Director | Option exercise / conversion | 407 | $0.00 | $0 | Form 4 |
| 2026-04-21 | EDWARDS JEFFREY L | Director | Option exercise / conversion (derivative) | 407 | $0.00 | $0 | Form 4 |
| 2026-04-21 | EDWARDS JEFFREY L | Director | Grant / award / vesting (derivative) | 369 | $0.00 | $0 | Form 4 |
| 2026-04-21 | EDWARDS JEFFREY L | Director | Option exercise / conversion | 407 | $0.00 | $0 | Form 4 |
| 2026-04-21 | PEI MELINDA LITHERLAND | Director | Option exercise / conversion (derivative) | 407 | $0.00 | $0 | Form 4 |
| 2026-04-21 | PEI MELINDA LITHERLAND | Director | Grant / award / vesting (derivative) | 369 | $0.00 | $0 | Form 4 |
| 2026-04-21 | PEI MELINDA LITHERLAND | Director | Option exercise / conversion | 407 | $0.00 | $0 | Form 4 |
| 2026-04-21 | Hinckley Greg K | Director | Option exercise / conversion (derivative) | 407 | $0.00 | $0 | Form 4 |
| 2026-04-21 | Hinckley Greg K | Director | Grant / award / vesting (derivative) | 369 | $0.00 | $0 | Form 4 |
| 2026-04-21 | Hinckley Greg K | Director | Option exercise / conversion | 407 | $0.00 | $0 | Form 4 |
| 2025-11-06 | BARRY JAMES | Officer (EVP, President, LSG) | Open-market sale | 700 | $306.18 | $214.3K | Form 4 |
| 2025-10-24 | DiVincenzo Jonathan P. | Officer (President & COO) | Option exercise / conversion (derivative) | 1,869 | $0.00 | $0 | Form 4 |
| 2025-10-24 | DiVincenzo Jonathan P. | Officer (President & COO) | Shares withheld for taxes / exercise cost | 950 | $339.75 | $322.8K | Form 4 |
| 2025-10-24 | DiVincenzo Jonathan P. | Officer (President & COO) | Option exercise / conversion | 1,869 | $0.00 | $0 | Form 4 |
| 2025-10-20 | EVRAN SEDAT | Officer (EVP, Global Supply Chain) | Option exercise / conversion (derivative) | 1,044 | $0.00 | $0 | Form 4 |
| 2025-10-20 | EVRAN SEDAT | Officer (EVP, Global Supply Chain) | Shares withheld for taxes / exercise cost | 335 | $321.90 | $107.8K | Form 4 |
| 2025-10-20 | EVRAN SEDAT | Officer (EVP, Global Supply Chain) | Option exercise / conversion | 1,044 | $0.00 | $0 | Form 4 |
| 2025-09-06 | Lakkaraju Roop Kalyan | Officer (EVP, Chief Financial Officer) | Option exercise / conversion (derivative) | 1,535 | $0.00 | $0 | Form 4 |
| 2025-09-06 | Lakkaraju Roop Kalyan | Officer (EVP, Chief Financial Officer) | Shares withheld for taxes / exercise cost | 550 | $295.43 | $162.5K | Form 4 |
| 2025-09-06 | Lakkaraju Roop Kalyan | Officer (EVP, Chief Financial Officer) | Option exercise / conversion | 1,535 | $0.00 | $0 | Form 4 |
| 2025-09-06 | EVRAN SEDAT | Officer (EVP, Global Supply Chain) | Option exercise / conversion (derivative) | 864 | $0.00 | $0 | Form 4 |
| 2025-09-06 | EVRAN SEDAT | Officer (EVP, Global Supply Chain) | Shares withheld for taxes / exercise cost | 277 | $295.43 | $81.8K | Form 4 |
| 2025-09-06 | EVRAN SEDAT | Officer (EVP, Global Supply Chain) | Option exercise / conversion | 864 | $0.00 | $0 | Form 4 |
| 2025-09-05 | Lakkaraju Roop Kalyan | Officer (EVP, Chief Financial Officer) | Grant / award / vesting (derivative) | 5,480 | $0.00 | $0 | Form 4 |
| 2025-09-05 | EVRAN SEDAT | Officer (EVP, Global Supply Chain) | Grant / award / vesting (derivative) | 4,110 | $0.00 | $0 | Form 4 |
Ask the chat about BIO's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: Bio-Rad Laboratories (BIO).
Last updated 2026-05-11 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.